The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
The importance of new companies for drug discovery: origins of a decade of new drugs
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regional advantage: culture and competition in Silicon Valley and Route 128
(1994) · Choice Reviews Online · doi:10.5860/choice.32-1166 · Cited by 4,263
The New Argonauts. Regional Advantage in a Global Economy
Frenken, K. (2009) · Regional Studies · doi:10.1080/00343400903132601 · Cited by 1,392
Lessons from 60 years of pharmaceutical innovation
Munos, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2961 · Cited by 1,207
Regional Advantage: Culture and Competition in Silicon Valley and Route 128
Chandler, A. D., & Saxenian, A. (1995) · The New England Quarterly · doi:10.2307/365972 · Cited by 842
Saxenian, A. (1996) · Harvard University Press eBooks · doi:10.2307/j.ctvjnrsqh · Cited by 538
Science Business: The Promise, the Reality and the Future of Biotech
Li, W. (2007) · Journal of Commercial Biotechnology · doi:10.1057/palgrave.jcb.3050059 · Cited by 409
The Rigid Disk Drive Industry: A History of Commercial and Technological Turbulence
Christensen, C. M. (1993) · Business History Review · doi:10.2307/3116804 · Cited by 366
Science Business: The Promise, the Reality and the Future of Biotech
Li, W. (1969) · Journal of Commercial Biotechnology · doi:10.5912/jcb219 · Cited by 340
Rebuilding the R&D engine in big pharma.
Garnier, J.-P. (2008) · PubMed · Cited by 228
Adopting Orphan Drugs — Two Dozen Years of Treating Rare Diseases
Haffner, M. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmp058317 · Cited by 162
Visualizing patent statistics by means of social network analysis tools
Sternitzke, C., Bartkowski, A., & Schramm, R. (2007) · World Patent Information · doi:10.1016/j.wpi.2007.08.003 · Cited by 161
Whitley, R. D., Glaeser, J., & Engwall, L. (2010) · Research Explorer (The University of Manchester) · Cited by 145
A historical sketch of the discovery and development of HIV-1 integrase inhibitors
Savarino, A. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.12.1507 · Cited by 140
KNELLER, R. W. (2007) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199268801.001.0001 · Cited by 51
Self-citationZucker, L. G., & Darby, M. R. (1996) · American Behavioral Scientist · doi:10.1177/0002764296039008003 · Cited by 25
KNELLER, R. W. (2005) · Nature Biotechnology · doi:10.1038/nbt0505-529 · Cited by 16
Self-citation
Cited by
The productivity crisis in pharmaceutical R&D
Pammolli, F., Magazzini, L., & Riccaboni, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3405 · Cited by 918
The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform
Kesselheim, A. S., Avorn, J., & Sarpatwari, A. (2016) · JAMA · doi:10.1001/jama.2016.11237 · Cited by 592
Hypoxia-targeted drug delivery
Sharma, A., Arambula, J. F., Koo, S., Kumar, R., Singh, H., Sessler, J. L., & Kim, J. S. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00304a · Cited by 542
Drug discovery in pharmaceutical industry: productivity challenges and trends
Khanna, I. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.05.007 · Cited by 479
The antibiotic resistance crisis, with a focus on the United States
Martens, E., & Demain, A. L. (2017) · The Journal of Antibiotics · doi:10.1038/ja.2017.30 · Cited by 445
Metadata
- Authors
- Kneller, R.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2010-10-29
- Volume
- 9
- Issue
- 11
- Pages
- 867-882
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2093858501
- Cited by
- 344
- References
- 16
- FWCI
- 8.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.